<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20391" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Juvenile Dermatomyositis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gara</surname>
            <given-names>Soumaya</given-names>
          </name>
          <aff>Charles Nocolle Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jamil</surname>
            <given-names>Radia T.</given-names>
          </name>
          <aff>Allama Iqbal Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muse</surname>
            <given-names>Mikel E.</given-names>
          </name>
          <aff>Campbell</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Litaiem</surname>
            <given-names>Noureddine</given-names>
          </name>
          <aff>University of Tunis El Manar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Soumaya Gara declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Radia Jamil declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mikel Muse declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noureddine Litaiem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20391.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Dermatomyositis is a rare autoimmune inflammatory myositis of unknown etiology affecting both children and adults. It involves striated muscles and skin. The juvenile form is associated with multisystemic vasculitis and a high frequency of calcinosis. However, unlike the adult form, it does not have an increased risk of malignancy. This activity explains when this condition should be considered, articulates how to properly evaluate for this condition, and highlights the interprofessional team's role in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the frequency of dermatomyositis.</p></list-item><list-item><p>Summarize the expected pathophysiologic findings expected in juvenile dermatomyositis.</p></list-item><list-item><p>Review the medical treatment of juvenile dermatomyositis.</p></list-item><list-item><p>Outline the importance of enhancing care coordination among the interprofessional team to ensure proper evaluation and management of juvenile dermatomyositis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20391">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20391.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Dermatomyositis is a rare autoimmune inflammatory myositis of unknown etiology affecting both children and adults. It involves striated muscles and skin. The juvenile form, juvenile dermatomyositis (JDM) is associated with multisystemic vasculitis and a high frequency of calcinosis, Gottron papules, symmetrical proximal muscle weakness, and a heliotrope rash. However, unlike the adult form, it does not have an increased risk of malignancy.<xref ref-type="bibr" rid="article-20391.r1">[1]</xref></p>
      </sec>
      <sec id="article-20391.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Dermatomyositis is an inflammatory myopathy distinguished by a mononuclear inflammatory infiltrate of the striated muscle. Genetic susceptibility is no longer in doubt since predisposing&#x000a0;human leukocyte antigen (HLA) systems have been identified. There is an activation of the complement leading to the deposition of the membrane attack complex in the wall of blood vessels, which causes microangiopathy and an inflammatory reaction. Because the disorder appears to have seasonal clustering, it is believed that some infectious organisms may be playing a role in self-tolerance and generation of the autoimmune response. Infections implicated include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Parvovirus B19</p>
          </list-item>
          <list-item>
            <p>Coxsackievirus</p>
          </list-item>
          <list-item>
            <p>Streptococcus</p>
          </list-item>
          <list-item>
            <p>Enteroviruses</p>
          </list-item>
        </list>
        <p>Non-infectious agents implicated include silica exposure, silicone implants, and medications that decrease lipids. There is a strong association of JDM with HLA-DR3.</p>
      </sec>
      <sec id="article-20391.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The mean age at onset of the disease is around 7 years, with earlier onset in girls. The mean time between the onset of the first symptoms and confirming the diagnosis is&#x000a0;6 months, ranging from&#x000a0;5 weeks to&#x000a0;2 years. The disorder is more common in females than males; in addition, JDM is more frequent in children of the White population than in other races.</p>
      </sec>
      <sec id="article-20391.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>It is believed that autoantibodies are directed against an unknown endothelial antigen that is responsible for vascular injury. Both T and B cells appear to play a dominant role in the disease pathophysiology with the generation of numerous cytokines, including interleukin 6 and 17. It appears that type 1 interferon-inducible genes may play a critical role in the pathogenesis of dermatomyositis.</p>
      </sec>
      <sec id="article-20391.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In JDM, the clinical features are usually insidious. Muscle weakness is the main reason for consultation, usually accompanied by systemic signs like asthenia, anorexia, irritability, pain, fever, and deterioration of one's general condition. The dermatological manifestations are like&#x000a0;those of adults&#x000a0;and are highly characteristic. Their recognition is essential because they can precede muscular signs. The periorbital violaceous patches like frames of glasses are almost pathognomonic&#x000a0;as well as Gottron papules.<xref ref-type="bibr" rid="article-20391.r2">[2]</xref><xref ref-type="bibr" rid="article-20391.r3">[3]</xref>&#x000a0;These latter&#x000a0;are found in 30% to 70% of cases and are easy to recognize.</p>
        <p>Violaceous papules are usually seen over the metacarpophalangeal area, the proximal and distal interphalangeal joints of hands, and less commonly, in the extensor surfaces of elbows and knees. One can also observe painful periungual erythema with telangiectasia, cuticular hypertrophy, facial edema, erythematous patches involving the "V-neck," shoulders anterior chest wall, and Raynaud phenomenon. More rarely, there are skin lesions of cutaneous vasculitis and photosensitivity. The muscular deficit is usually progressive, symmetric, bilateral, proximal, and non-selective, involving striated muscles of the pelvis and shoulders. The muscle weakness intensity varies from one patient to another, ranging from simple myalgia to a severe muscle deficit.</p>
        <p>Children may report difficulties in dressing, combing hair, and climbing stairs. During evolution, calcinosis may occur more commonly in children than in adults. These calcifications arise from subcutaneous tissues or deeper locations such as musculoaponeurotic structures. The commonest sites of calcinosis include elbows, knees, buttocks, and trauma areas. Its evolution is unpredictable. It can regress spontaneously, and ulcerate with a risk of secondary infections causing major aesthetic and functional sequelae. It can mimic&#x000a0;cold abscesses.<xref ref-type="bibr" rid="article-20391.r4">[4]</xref>&#x000a0;No standardized approach to the management of calcinosis associated with JDM has&#x000a0;been established. Its incidence may decrease with early treatment by systemic corticosteroid therapy at high doses. Experienced physicians are more likely to use bisphosphonates as first-line treatment.<xref ref-type="bibr" rid="article-20391.r5">[5]</xref><xref ref-type="bibr" rid="article-20391.r6">[6]</xref>&#x000a0;The involvement of the pharyngeal and esophageal muscles is responsible for dysphonia, dysphagia, and dyspnea, affecting the vital prognosis. Transferring the patient for admission to the intensive care unit is necessary to initiate appropriate&#x000a0;treatment.<xref ref-type="bibr" rid="article-20391.r7">[7]</xref>&#x000a0;Amyopathic forms of JDM are rare.<xref ref-type="bibr" rid="article-20391.r8">[8]</xref>&#x000a0;They are characterized by typical skin manifestations without muscle involvement. Serum muscle enzymes, electromyographic examination, and muscle biopsy are normal. There is usually no calcinosis or vasculopathy. The prognosis is excellent.</p>
        <p>Myocardial involvement may cause ventricular arrhythmias. Lipodystrophy usually occurs after a long evolution. The fat loss is slow and progressive, typically affecting the upper part of the trunk. It can be associated with hirsutism, hepatomegaly, and acanthosis nigricans lesions. JDM is associated with a high risk of cardiovascular and cerebrovascular comorbidities.<xref ref-type="bibr" rid="article-20391.r9">[9]</xref>&#x000a0;Pulmonary manifestations include interstitial lung disease and respiratory muscle involvement.<xref ref-type="bibr" rid="article-20391.r10">[10]</xref></p>
      </sec>
      <sec id="article-20391.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>An abnormal elevation of serum activities of muscle enzymes is the most common biological finding in JDM. &#x000a0;Elevation of creatine kinase is expected in 75% to 85% of cases with average values around 2000 U/L plus or minus 1000. A normal rate can be observed at the beginning of the disease and in amyopathic forms. Regular creatine phosphokinase monitoring is recommended during the evolution under treatment to evaluate its effectiveness. Other laboratory workups include erythrocyte sedimentation rate, lupus profile, and myositis-specific antibodies.</p>
        <p>The electromyogram shows a myogenic pattern. A muscle biopsy confirms the diagnosis. Some histological abnormalities are common to other myositides: myofiber degeneration and an inflammatory mononuclear infiltrate. Other findings are more specific, for example, a highly characteristic perifascicular atrophy, perivascular inflammatory infiltrate, and sometimes intravascular microthrombi. Magnetic resonance imaging is a non-invasive tool used to guide the muscle biopsy site to optimize its sensitivity. Muscle edema is the major abnormality observed on MRI, particularly in the T2 sequence with fat suppression or short tau inversion recovery sequence. This edema is usually proximal and symmetrical but might be focal and distal. The signal intensity seems to be correlated with an aggressive, chronic disease course.<xref ref-type="bibr" rid="article-20391.r11">[11]</xref></p>
      </sec>
      <sec id="article-20391.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Systemic corticosteroids are the established primary treatment for the management of JDM. As yet, there is no consensus regarding the dose regimen and the therapeutic modalities. It is recommended to initiate the treatment with 1 milligram per kilogram of daily equivalent prednisone. Intravenous treatment is preferable in the&#x000a0;case&#x000a0;of gastrointestinal involvement. This late is known to be associated with vasculitis causing malabsorption. Long-term steroid treatment is usually required to achieve complete remission. It should be gradually decreased. Adjunctive hygienic-dietary measures, as well as daily supplementation with calcium and vitamin D, &#x000a0;must be systematic. However, these children are at high risk of osteoporosis.</p>
        <p>In cases of therapeutic failure or significant side effects under steroid therapy, the use of subcutaneous methotrexate should be considered. Combining corticosteroids and methotrexate is a good alternative to control disease activity without significant adverse reactions.<xref ref-type="bibr" rid="article-20391.r12">[12]</xref>&#x000a0;Using hydroxychloroquine may be a new therapeutic approach. Targeted biotherapies (infliximab, rituximab) may be indicated in refractory forms of JDM. Only controlled and randomized clinical trials will be able to&#x000a0;validate their safety in children.<xref ref-type="bibr" rid="article-20391.r13">[13]</xref>&#x000a0;Therapeutic abstention in amyopathic JDM is the rule. In this case, patients generally&#x000a0;remain&#x000a0;asymptomatic even after several years of evolution. Physical therapy is an important part of the treatment. It should be started as soon as symptoms are under control. It aims to rebuild muscle strength and prevent joint contraction.<xref ref-type="bibr" rid="article-20391.r14">[14]</xref>&#x000a0;For those who have dysphagia, occupational and speech therapy is&#x000a0;necessary to educate the patient/family&#x000a0;regarding food consistency and proper positioning of the chin, head, and tongue.</p>
      </sec>
      <sec id="article-20391.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for JDM includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Myositis</p>
          </list-item>
          <list-item>
            <p>Lupus</p>
          </list-item>
          <list-item>
            <p>Raynaud phenomenon</p>
          </list-item>
          <list-item>
            <p>Scleroderma</p>
          </list-item>
          <list-item>
            <p>Eczema</p>
          </list-item>
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Tinea</p>
          </list-item>
          <list-item>
            <p>Muscular dystrophy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20391.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The condition's evolution is unpredictable. The disease may have a monocyclic, polycyclic, or chronic course. The prognosis has significantly improved over recent years with the emergence of new therapeutic options. Early treatment and close monitoring may lead to better control of the disease. However, developing countries still have a high mortality rate.<xref ref-type="bibr" rid="article-20391.r15">[15]</xref>&#x000a0;The major causes of death are usually severe muscle weakness, super-added infection, gastrointestinal vasculitis with a&#x000a0;risk of bowel perforation, myocardial failure, and respiratory distress. Calcinosis cutis occurs in 30% of patients and is associated with high morbidity. Besides poor cosmesis, it causes pain and limits function. Calcinosis cutis may also lead to contractures, ulcerations, and nerve entrapment. Before the advent of corticosteroids, one-third of patients spontaneously improved, one-third had a chronic, lingering course, and one-third died from the disease. JDM is usually not associated with the development of malignancies, unlike the adult form.<xref ref-type="bibr" rid="article-20391.r16">[16]</xref></p>
      </sec>
      <sec id="article-20391.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Potential complications&#x000a0;accompanying dermatomyositis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dysphagia can occur when esophageal muscles are affected, leading to weight loss and malnourishment.</p>
          </list-item>
          <list-item>
            <p>Aspiration pneumonia; issues affecting swallowing can also lead to the inspiration of food particles, liquids, or saliva.</p>
          </list-item>
          <list-item>
            <p>Problems breathing; if there is the involvement of the chest or thorax muscles, it can result in dyspnea.</p>
          </list-item>
          <list-item>
            <p>Calcium deposits; as the disease progresses, can present in the muscles, connective tissues, and skin.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20391.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Having a child with JDM may impact the family's quality of life negatively.<xref ref-type="bibr" rid="article-20391.r17">[17]</xref>&#x000a0;Psychological assistance is necessary for the child and their parents.</p>
      </sec>
      <sec id="article-20391.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dermatomyositis is a rare autoimmune inflammatory myositis of unknown etiology affecting both children and adults. It involves striated muscles and skin.&#x000a0;The juvenile form&#x000a0;is associated&#x000a0;with multisystemic vasculitis and a high frequency of calcinosis. However, unlike the adult form, it does not have an increased risk of malignancy.<xref ref-type="bibr" rid="article-20391.r1">[1]</xref>&#x000a0;The disorder is best managed by an interprofessional team that includes a rheumatologist, dermatologist, neurologist, gastroenterologist, and pediatrician. Once the disorder is diagnosed, its progression is unpredictable, but the symptoms can be managed with treatment. However, delay in diagnosis can lead to premature death.&#x000a0;The major causes of death are usually severe muscle weakness, super-added infection, gastrointestinal vasculitis with a&#x000a0;risk of bowel perforation, myocardial failure, and respiratory distress. JDM&#x000a0;is usually not associated&#x000a0;with the development of malignancies, unlike the adult form. An interprofessional approach involving nurses, pharmacists, and clinicians will result in the best outcomes.<xref ref-type="bibr" rid="article-20391.r16">[16]</xref></p>
      </sec>
      <sec id="article-20391.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20391">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/child-health/juvenile-dermatomyositis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20391">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20391/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20391">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20391.s15">
        <title>References</title>
        <ref id="article-20391.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lundberg</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Tj&#x000e4;rnlund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bottai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Werth</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Pilkington</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arnardottir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chinoy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Dank&#x000f3;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Torre</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kohsaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lachenbruch</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oddis</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Olesinska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rutkowska-Sak</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sanner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Selva-O'Callaghan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Vencovsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ytterberg</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Rider</surname>
                <given-names>LG</given-names>
              </name>
              <collab>International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland)</collab>
            </person-group>
            <article-title>2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>76</volume>
            <issue>12</issue>
            <fpage>1955</fpage>
            <page-range>1955-1964</page-range>
            <pub-id pub-id-type="pmid">29079590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sukumaran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vijayan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Heliotrope Rash and Gottron Papules in a Child with Juvenile Dermatomyositis.</article-title>
            <source>J Pediatr</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>171</volume>
            <fpage>318.e1</fpage>
            <pub-id pub-id-type="pmid">26817590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Expanding Spectrum of Gottron Papules in Juvenile Dermatomyositis.</article-title>
            <source>Indian J Pediatr</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-243</page-range>
            <pub-id pub-id-type="pmid">27924465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagar</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Bharati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sheriff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Priyadarshini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chumber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kabra</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Calcinosis in juvenile dermatomyositis mimicking cold abscess.</article-title>
            <source>Natl Med J India</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>87</fpage>
            <page-range>87-8</page-range>
            <pub-id pub-id-type="pmid">27586213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orandi</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Baszis</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Dharnidharka</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hoeltzel</surname>
                <given-names>MF</given-names>
              </name>
              <collab>CARRA Juvenile Myositis subgroup</collab>
            </person-group>
            <article-title>Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).</article-title>
            <source>Pediatr Rheumatol Online J</source>
            <year>2017</year>
            <month>Sep</month>
            <day>21</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <pub-id pub-id-type="pmid">28934971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kalaivani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kabra</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.</article-title>
            <source>Rheumatol Int</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>961</fpage>
            <page-range>961-5</page-range>
            <pub-id pub-id-type="pmid">27007612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Besan&#x000e7;on</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brochard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dupic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gitiaux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delville</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quartier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saire</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Talbotec</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bodemer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bader-Meunier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2017</year>
            <month>Oct</month>
            <day>01</day>
            <volume>56</volume>
            <issue>10</issue>
            <fpage>1814</fpage>
            <page-range>1814-1816</page-range>
            <pub-id pub-id-type="pmid">28957568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oberle</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Co</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>How Often are Pediatric Patients with Clinically Amyopathic Dermatomyositis Truly Amyopathic?</article-title>
            <source>Pediatr Dermatol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-57</page-range>
            <pub-id pub-id-type="pmid">27813167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverberg</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kwa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kwa</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Laumann</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ardalan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>694</fpage>
            <page-range>694-702</page-range>
            <pub-id pub-id-type="pmid">29373707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pouessel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Deschildre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Bourgeois</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cuisset</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Catteau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Karila</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>N&#x000e8;ve</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thumerelle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Quartier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tillie-Leblond</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The lung is involved in juvenile dermatomyositis.</article-title>
            <source>Pediatr Pulmonol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>10</issue>
            <fpage>1016</fpage>
            <page-range>1016-25</page-range>
            <pub-id pub-id-type="pmid">23281200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ladd</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Salisbury</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Laor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lovell</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bove</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>197</volume>
            <issue>1</issue>
            <fpage>W153</fpage>
            <page-range>W153-8</page-range>
            <pub-id pub-id-type="pmid">21700978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Pain</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.</article-title>
            <source>Indian J Pediatr</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-71</page-range>
            <pub-id pub-id-type="pmid">26489640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aggarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loganathan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koontz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Oddis</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>247</fpage>
            <page-range>247-254</page-range>
            <pub-id pub-id-type="pmid">27837048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papadopoulou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wedderburn</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Juvenile Dermatomyositis: An Update.</article-title>
            <source>Paediatr Drugs</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>423</fpage>
            <page-range>423-434</page-range>
            <pub-id pub-id-type="pmid">28550457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aulakh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rawat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.</article-title>
            <source>Clin Rheumatol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>1675</fpage>
            <page-range>1675-9</page-range>
            <pub-id pub-id-type="pmid">25053380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dare</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Juvenile dermatomyositis as a paraneoplastic phenomenon: an update.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>189</fpage>
            <page-range>189-91</page-range>
            <pub-id pub-id-type="pmid">20057323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20391.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kountz-Edwards</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gannon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cordova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Packman</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The family impact of caring for a child with juvenile dermatomyositis.</article-title>
            <source>Chronic Illn</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>262</fpage>
            <page-range>262-274</page-range>
            <pub-id pub-id-type="pmid">28133992</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
